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Purpose/Objective: Re-irradiation of high-grade glioma (HGG) using 
modern delivery techniques and advanced imaging 18F-flouroethyl-
tyrosine (FET)-PET and MRI have not been systematically evaluated. 
The initial results of a prospective, FET-PET and MRI-guided, dose-
escalation study of previously irradiated HGG are presented.  
Materials and Methods: Patients with performance status 0-2 with 
localized disease progression despite standard therapy were eligible 
to be included. The target was defined using MRI (Siemens 1.5 T 
scanner, T1 w/Gd contrast) and FET-PET (Siemens mCT brain scanner 
20 min after injection of 200 MBq FET, threshold: 1.6 of SUV mean in 
background) and these volumes were fused. A 2 mm PTV (planning 
target volume) margin was added. Hypofractionated stereotactic 
radiotherapy (SRT) was planned in Eclipse dose planning system 
(Varian) and given as Volumetric Modulated Arc Therapy on a Novalis 
Tx accelerator (Varian/BrainLab). Total doses to organs at risk 
(brainstem, optic chiasm) were calculated using primary and current 
treatment plans.  
Results: Fifteen patients were referred to treatment in dose level one 
(3.5 Gy x 10, 5 F/W) between December 1, 2011 and August 1, 2012. 
Twelve were eligible to be included. Histological diagnoses were 
glioblastoma multiforme (83%) and anaplastic astrocytoma WHO grade 
III. All patients had received prior focal radiotherapy (44 Gy-60 Gy) 
and the median interval since primary RT was 26.7 months (range: 
14.3-67.7 months). In 11/12 cases increased FET uptake consistent 
with malignant disease was detected. The median GTV MR (defined by 
T1 MR with contrast) was 23.8 cm3 (range: 7.9-52.4 cm3). The 
combined GTV used for planning (based on MRI and PET) was larger 
than the GTV MR for 11 out of 12 patients by a median of 26% (range: 
0-283%). The median PTV volume was 53.4 cm3 (range: 21.1-91.3 
cm3). The median doses to chiasm and brainstem were 0.9 (range: 
0.2-22.8 Gy) and 1.2 (range: 0.4-26.9 Gy) in 2-Gy equivalent fractions 
(α/β=3), respectively. Doses to the chiasm and brainstem exceeded 15 
Gy in 1 and 2 cases of temporal tumors, respectively. All patients 
completed treatment as planned. No serious (grade 2+ CTC) acute 
adverse events were observed during treatment or in the 4 following 
weeks. One patient experienced dizziness and unilateral motor 
dysfunction 4 weeks after treatment. Disease progression was 
suspected but the patient withdrew from the study. No serious late 
side effects have been observed. Minimum follow-up time for all 
(surviving) patients is currently 3 months.  
Conclusions: Re-irradiation using 3.5 Gy x 10 to localized recurrences 
of HGG using MR and FET-PET for target delineation was feasible and 
well tolerated. Using FET-PET for target delineation increased the size 
of the GTV by a median of 26%. Only in case of temporal tumors did 
doses to organs at risk pose a planning challenge. The study is ongoing 
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Purpose/Objective: Standard therapy for patients with brain 
metastases was WBRT with 30Gy/10fx in our institution. We report 
about our newly developed radiotherapy procedure with 
hypofractionated dose intensification to metastases with or without 
simultaneously applied low dose prophylactic cranial irradiation (PCI) 
to the remaining brain. 
Materials and Methods: From 6/2010 until 5/2012 61 patients with 1-
4 brain metastases and Karnofsky performance score > 50 were 
treated with our new therapy concept. 21 Patients received local 
treatment only whereas 40 patients assumed to have a higher risk for 
new distant brain metastases were treated with simultaneous low 
dose PCI. 20 patients were irradiated after gross tumour resection. 
Macroscopic metastases were treated to 60Gy/15fx (BED10 84Gy, 
BED3 140Gy) and PCI was applied with 27Gy/15fx (BED10 32Gy, BED3 
43Gy) using RapidArc technique with simultaneous integrated boost 
(SIB). Following resection of the metastasis the resection cavity was 
irradiated to 48Gy/15fx (BED10 63Gy), residual/unresected 
macroscopic tumour to 60Gy/15fx and the remaining brain if indicated 
to 27Gy/15fx (PCI). CTV was equal to GTV and a 3-5 mm margin was 
used for the PTV PTV. The minimum dose for the metastases was 95% 
of the prescribed dose, whereas the median dose for the whole brain 
was 27 Gy. All patients were followed prospectively with CT or MRI 
scan every 2-4 months until deterioration. Toxicity was assessed by 
the treating physician using CTCAE 4.0. Statistical analysis was 
performed with Kaplan Meier and Logrank test. Multivariate analysis 
was performed using Cox-regression.  
Results: The median follow-up was 10.7 months (range 4.1-26.1 
months). The treatment was well tolerated and no grade 3 or higher 
acute toxicity was observed. One patient with 4 small metastases who 
was treated with 60Gy/15fx and PCI died possibly due to progressive 
radionecrosis 15 months after treatment. Local recurrence-free 
survival after treatment with 60Gy/15fx has been 100%, whereas one 
metastasis relapsed after resection and postoperative RT (48Gy/15fx). 
Regional recurrence-free survival within 9 months was 68% with PCI 
and 59% without PCI, respectively (p=0.23). 39 patients died during 
follow-up and the overall survival at 12 months was 44%. Median 
survival time in univariate analysis was significantly better for 
patients younger than 60 years (13.0 vs. 7.5 months, p=0.03), patients 
with RPA I (18 vs. 7.6 months, p=0.005), patients with controlled 
extracranial disease (15 vs. 7 months, p=0.005) and patients who 
received PCI (11.5 vs. 6.3 months, p=0.02). Gross tumour resection 
and solitary metastasis did not result in significantly better survival. In 
multivariate Cox regression analysis RPA I class and PCI remained 
statistically significant predictors for improved survival. 
Conclusions: Dose intensified irradiation to macroscopic brain 
metastases or resection cavities can be combined with a well 
tolerated prophylactic cranial irradiation using SIB. Local tumour 
control appears to be excellent, distant brain failure was moderate 
and overall survival was promising. 
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Purpose/Objective: To define the maximum tolerable dose (MTD) of 
temozolomide concomitant to radiotherapy in patients with Primary 
Central Nervous System Lymphoma (PCNLSL), previously treated with 
high dose Methotrexate (HD-MTX). 
Materials and Methods: Patients (≥18 yrs) with histologically proven 
diagnosis of PCNSL, treated with two cycles of HD-MTX, were 
enrolled. For radiation treatment, Clinical Target Volumes (CTVs) 
were: whole brain plus leptomeninges until C2 (CTV2) (30 Gy in 15 
fractions), and initial site of disease plus residual mass if present 
(CTV1) (3600-4600 cGy depending on HD-MTX response). Dose 
escalation of concomitant Temozolomide (TMZ) until standard 
concomitant to radiotherapy dose advanced using a standard 3+3 
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design; 3 level dose were tested: 50-60-75 mg/mq/die for 5 
days/week. Primary endpoint was to define the Maximum Tollerate 
Dose (MTD); acute toxicity (RTOG/EORTC) considered dose-limiting 
was: any grade >4 hematological toxicity or any grade 3 or 4 hepatic 
toxicity. Secondary endpoint were clinical outcomes in terms of 
radiation therapy response rate, disease free survival (DFS) and 
overall survival (OS). 
Results: From April 2007 to June 2011, 9 patients were enrolled: 5 
male and 4 female. Median age was 67 yrs (range 50-76). IELSG at 
diagnosis was 0 in 2 patients, 1 and 2 in three patients respectively, 4 
in only one patients. Three of nine patients received only one cycle of 
HD-MTX because of hepatic, renal and haematological toxicity 
respectively. Seven patients had single lesion while 2 patients had 
multiple lesions; total lesions were 12. After HD-MTX 4/12 lesions had 
unconfirmed complete response (CRu), 5/12 had partial response (PR) 
and 3 showed progressive disease (PD). None dose-limiting toxicities 
was recorded. Acute toxicity was very low: one patients developed 
grade 2 white blood cells toxicity, and two patients developed grade 1 
hepatic toxicity. At a median follow up of 43 months, (range 18-69) 
6/9 patients (66.6%) are alive without disease, two older patients died 
because of disease and one patients died because of other causes. 
Median OS is 50 months with at 3 yrs OS of 78%. Median DFS has not 
yet reached, while at 3-yrs DFS is 74%. 
Conclusions: The MTDs for the combination of RT and Temozolomide 
after HD-MTX was not reached; standard dose of Temozolomide (75 
mg/mq/die) can be safely used associated to radiotherapy. Further 
studies are warranted to define clinical outcomes. 
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Purpose/Objective: Complex skull base tumors, such as large 
meningiomas and schwannomas, pose unique management challenges 
because of their irregular shapes, proximity and involvement of 
critical normal structures, and variable tumor volumes. Surgical 
decompression is often desired to relieve mass effect on brainstem 
and other critical structures, including cranial nerves, but gross total 
removal is often not possible without significant neurologic morbidity. 
We present preliminary outcomes of a feasibility study of planned 
subtotal resection with intelligent, computer-assisted, intra-operative 
guidance (Adaptive Hybrid Surgery) for management of these 
patients. 
Materials and Methods: To date, five patients with complex skull base 
tumors (2 large vestibular schwannomas, and 3 petroclival 
meningiomas) underwent computer-assisted, planned subtotal 
resection (STR), three of which were staged resections, followed by 
adjuvant stereotactic radiotherapy (SRT) or radiosurgery (SRS). Pre-
operative RT plans (designed to maximize tumor coverage) were 
uploaded into cranial navigation and stereotactic planning system. 
Resection approach and goals were planned pre-operatively, and 
extent of resection (EOR) was defined intraoperatively, iteratively, 
and in real-time by the operating neurosurgeon. Expected post-
operative SRT or SRS toxicity was estimated in near real-time using a 
set of pre-defined parameters during surgery to inform and guide 
resection extent with the aim of sculpting the tumor to create an 
ideal radiosurgical target. When estimates of post-op RT toxicity met 
predefined criteria, resection was halted and patients went on to 
received post-operative RT (within 1 month of surgery). 
Results: Pathologic review of surgical specimens was consistent with 
benign tumor histology in all five cases. Pre- and post-operative RT 
planning was performed successfully in all cases; without surgical 
resection, all 5 lesions would require conventionally-fractionated SRT 
in the adjuvant setting; however, 3 cases were eligible for (and 
successfully converted to) a 5-day SRS treatment following computer-
guided tumor debulking and were treated in that manner. With 
median follow-up period of 20.0 months (range, 6-31 months), no 
tumor recurrences were observed and all patients experienced stable 
or improved neurologic function (one stable, 4 improved) compared to 
pre-operative baseline. 
Conclusions: We have demonstrated the feasibility of adaptive, multi-
modality management of complex skull base tumors with intra-
operative software guidance. The approach of guided and selective 
'tumor sculpting' in the setting of subtotal resection with planned 
adjuvant SRT is expected to result in tumor control rates that are in 
line with historical data, and has the potential to convert cases of 
adjuvant conventionally-fractionated SRT to SRS cases, thereby 
decreasing overall treatment time while minimizing both surgical and 
radiotherapy morbidity.  
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Purpose/Objective: To assess safety and efficacy of hypofractionated 
therapy followed by low dose radiation therapy (LDRT) combined with 
Temozolomide in adults with newly diagnosed Glioblastoma 
Multiforme (GBM).  
Materials and Methods: Patients (KPS > 70, age >18 years) who 
underwent to biopsy or who presented gross residual tumor after 
surgery were enrolled. Hypofractionated dose (30 Gy in ten fractions) 
combined with Temozolomide (75 mg/m2 daily from start to end RT) 
was delivered before LDRT. Beginning with second adjuvant TMZ (200 
mg/m2 daily for 5 days every 28 days) patients received two daily 
doses of 0.40 Gy, at least 4 hours apart, for 5 days; 2-4 cycles were 
planned. Conformal irradiation included the tumor bulk with surgical 
cavity, plus a 30-mm margin. The primary endpoints as safety, toxicity 
and tolerability were evaluated according to the Common Terminology 
Criteria for Adverse Events version 4.0. The secondary endpoints were 
the response, according to the RECIST Guidelines, the overall survival 
(OS) and the progression-free survival (PFS) calculated by the Kaplan-
Mayer method. 
Results: From June 2008 to January 2012, 20 patients (M/F: 1), with a 
median age was 64.5 years (range 43-75), were enrolled. All patients 
received the prescribed dose of 30 Gy. The median dose of LD-FRT 
was 12 Gy (range 3-24 Gy), equal to two cycles; 11/20 (55%) 
underwent to <2 cycles and 9/20 (45%) to > 2 cycles. All toxicities 
were reversible and only 5 patients (25%) presented hematologic 
toxicity, grade 1-2 of leukopenia and thrombocytopenia in 4/5 
patients. Regarding the whole sample median OS and PFS from initial 
diagnosis were 18 and 11 months, respectively. According to the 
number of cycles, a median OS of 8 months and PFS of 5 months was 
observed in patients underwent to <2 cycles while a median OS of 27 
months and PFS of 12 months when four cycles were administered. 
Conclusions: Hypofractionated regimen followed by LDRT combined 
with TMZ is safe, well tolerated and may prolong the survival of 
patients with GBM. Further investigation is warranted; a new trial 
with different hypofractionated and LDRT dose is ongoing.  
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Purpose/Objective: Prospective evaluation of outcomes, toxicity, and 
quality-of-life of patients with oropharyngeal cancer (OPC) treated by 
IMRT and stereotactic body radiotherapy boost. 
Materials and Methods: Between 2004 and 2011, 132 consecutive 
patients with T1-4N0-3 OPC were treated with (chemo)radiotherapy 
with 46-Gy of IMRT to the primary tumor and the neck followed by a 
boost to the primary tumor by means of the Cyberknife (stereotactic 
body radiotherapy). Patients with node-positive disease received neck 
dissection 2-3 weeks after finishing radiotherapy. Endpoints were 
locoregional control (LRC), disease-free survival (DFS), and overall 
survival (OS), toxicity using Common Terminology Criteria for Adverse 
Events v3.0 (CTCAE) and QoL-assessment using the EORTC QLQ-C30 
and QLQ-H&N35. 
Results: After a median follow-up of 30 months, the 3-year actuarial 
incidence of LRC, DFS, and OS were 93, 85%, and 76%, respectively. 
Nine locoregional failures were reported. No single failure was 
observed in patients with T1 or T2 and in patients with HPV-related 
disease. At the end of treatment, 26% of patients had tube feeding. 
On the mutltivariate analysis tumor stage, chemotherapy and 
unilateral neck irradiation were significantly correlated with tube 
feeding. For the whole group, the overall incidence of grade ≥2 late 
toxicity was 23%. The incidence of grade ≥2 late dysphagia and 
 
 
